|
mFOLFIRINOX Clinical Trials
14 actively recruiting trials across 7 locations
Pipeline
Phase 1: 4Phase 2: 4Phase 1/2: 2Phase 2/3: 3
Top Sponsors
- Zhejiang University1
- Washington University School of Medicine1
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
- Tango Therapeutics, Inc.1
- SONIRE Therapeutics Inc.1
Indications
- Cancer14
- Lung Cancer3
- Pancreatic Cancer2
- Adenocarcinoma, Pancreatic Ductal1
- Stage III Colon Cancer1
Other7 trials
Phase 2
Birmingham, Alabama1 trial
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
University of Alabama at Birmingham Cancer Center
Phase 2/3
Phoenix, Arizona1 trial
Scottsdale, Arizona1 trial
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Mayo Clinic Scottsdale
Phase 1/2
Los Angeles, California1 trial
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
USC Norris Comprehensive Cancer Center
Phase 2
New Haven, Connecticut1 trial
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
Yale University School of Medicine
Phase 1
Detroit, Michigan1 trial
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Karmanos Cancer Center
Phase 2/3
St Louis, Missouri1 trial
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.